Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 7 » Issue 1

Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures

Authors Weisenberg JLZ, Wong M

Published Date July 2011 Volume 2011:7(1) Pages 409—414

DOI http://dx.doi.org/10.2147/NDT.S14208

Published 7 July 2011

Judith LZ Weisenberg, Michael Wong
Department of Neurology, Washington University School of Medicine, St Louis, MO, USA

Abstract: Epilepsy is a common disease with significant morbidity and mortality. Approximately one-third of patients with epilepsy are refractory to available seizure medications, emphasizing the need to develop better drugs with novel mechanisms of action. Ezogabine, also known as retigabine, is a new potential adjunctive treatment for adults with intractable partial seizures. Ezogabine has a unique mechanism of action consisting of activating KCNQ2/3 (Kv7) potassium channels. Ezogabine has undergone a number of Phase II and III trials demonstrating efficacy at 600,900 and 1200 mg/day in a dose-dependent fashion. The most common adverse events with ezogabine are central nervous system effects, particularly dizziness and somnolence. Urologic symptoms, particularly urinary retention, represent a rare but unique side effect of ezogabine. Ezogabine is predominantly metabolized via glucuronidation. Its half-life is 8 hours, suggesting a need for three-times-a-day administration. Ezogabine exhibits minimal interactions with other seizure medications, except possibly lamotrigine. Ezogabine has potential for clinical applications in other medical conditions beyond epilepsy, such as neuropathic pain, neuromyotonia, and bipolar disease, but these are based primarily on experimental models.

Keywords: antiepileptic drug, epilepsy, ezogabine

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Readers of this article also read:

New developments in the treatment of partial-onset epilepsy

Besag FM, Patsalos PN

Neuropsychiatric Disease and Treatment 2012, 8:455-464

Published Date: 17 October 2012

The management of schizophrenia: focus on extended-release quetiapine fumarate

Peuskens J

Neuropsychiatric Disease and Treatment 2011, 7:549-564

Published Date: 21 September 2011

Role of sublingual asenapine in treatment of schizophrenia

Citrome L

Neuropsychiatric Disease and Treatment 2011, 7:325-339

Published Date: 26 May 2011

Aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence

McIntyre R, Yoon J, Jerrell JM, Liauw SS

Neuropsychiatric Disease and Treatment 2011, 7:319-323

Published Date: 25 May 2011

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder

Berman R, Thase M, Trivedi M, Hazel JA, Marler S, McQuade R, Carson W, Baker R, Marcus R

Neuropsychiatric Disease and Treatment 2011, 7:303-312

Published Date: 24 May 2011

Recurrent major depression, ataxia, and cardiomyopathy: association with a novel POLG mutation?

Verhoeven WMA, Egger JIM, Kremer BPH, de Pont BJHB, Marcelis CLM

Neuropsychiatric Disease and Treatment 2011, 7:293-296

Published Date: 15 May 2011

Psychiatric disorders in primary focal dystonia and in Parkinson’s disease

Fernando MV Dias, Arthur Kummer, Flávia CP Doyle, et al

Neuropsychiatric Disease and Treatment 2011, 7:111-116

Published Date: 14 March 2011

Evidence to practice: treatment of anxiety in individuals with autism spectrum disorders

Russell Lang, Richard Mahoney, Farah El Zein, et al

Neuropsychiatric Disease and Treatment 2011, 7:27-30

Published Date: 25 January 2011